Drug intelligence / Profile preview

nicotinamide + palmitoylethanolamide + oleoylethanolamide + spermidine

Development stage
Preclinical
Lead developer
Mimio Health
Modality
Small Molecules
Administration
Oral
01

Overview

This is a **combination product** containing four bioactive compounds: - **Nicotinamide**: a form of vitamin B3, important in NAD+ biosynthesis, cellular energy metabolism, DNA repair, and anti-inflammatory effects. - **Palmitoylethanolamide (PEA)**: an endogenous fatty acid amide that acts as a peroxisome proliferator-activated receptor alpha (**PPARα**) agonist, known for analgesic, anti-inflammatory, and neuroprotective properties[5][1]. - **Oleoylethanolamide (OEA)**: an endogenous lipid that acts as a PPARα agonist and GPR119 agonist, with roles in appetite regulation, body weight control, anti-inflammatory, antioxidant, and neuroprotective activities[4][2][1]. - **Spermidine**: a polyamine involved in cellular growth and autophagy, with proposed roles in promoting cellular health, longevity, and neuroprotection. No unique combination drug or widely marketed pharmaceutical product containing just these four ingredients is identified in authoritative pharmaceutical registries as of the latest reports. The components are often individually researched as dietary supplements or investigational agents.

02

Targets

Nicotinamide adenine dinucleotide biosynthesis pathway (NAD biosynthesis pathway)PPARA (Peroxisome proliferator-activated receptor alpha)GPR119 (Glucose-dependent insulinotropic receptor)Polyamine transporter

Beyond the preview

Go deeper on nicotinamide + palmitoylethanolamide + oleoylethanolamide + spermidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nicotinamide + palmitoylethanolamide + oleoylethanolamide + spermidine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call